Dyne Therapeutics (NASDAQ:DYN) Insider Johanna Friedl-Naderer Sells 900 Shares

Key Points

• Insider sale: Johanna Friedl-Naderer sold 900 Dyne Therapeutics shares for $21,915 at an average price of $24.35, reducing her position by 0.58%. The sale was made to cover tax withholding related to vested equity awards.
• Stock and earnings pressure: DYN fell 16.4% to $20.31 amid unusually heavy trading, while the company’s latest quarterly loss of $1.08 per share missed analysts’ $0.75 estimate.
• Analyst outlook remains positive: Wall Street’s consensus rating is “Moderate Buy,” with an average price target of $34.17 versus the current price. Investors are focused on upcoming clinical data for Dyne’s DM1 program, though a rival’s failed Phase 3 trial has increased concern about clinical execution risk.

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) insider Johanna Friedl-Naderer sold 900 shares of the business's stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $24.35, for a total transaction of $21,915.00. Following the completion of the transaction, the insider owned 153,082 shares in the company, valued at $3,727,546.70. The trade was a 0.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Johanna Friedl-Naderer also recently made the following trade(s):

• On Tuesday, September 8th, Johanna Friedl-Naderer sold 185 shares of Dyne Therapeutics stock. The stock was sold at an average price of $18.88, for a total transaction of $3,492.80.

Dyne Therapeutics Trading Down 16.4%

NASDAQ:DYN traded down $3.97 during mid-day trading on Tuesday, reaching $20.31. 17,067,421 shares of the company's stock traded hands, compared to its average volume of 2,151,348. The company has a 50 day moving average price of $24.86 and a 200-day moving average price of $20.45. The firm has a market capitalization of $3.79 billion, a price-to-earnings ratio of -6.10 and a beta of 1.08. The company has a debt-to-equity ratio of 0.28, a current ratio of 12.02 and a quick ratio of 12.02. Dyne Therapeutics, Inc. has a 12-month low of $11.92 and a 12-month high of $27.31.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.33). On average, sell-side analysts predict that Dyne Therapeutics, Inc. will post -3.47 earnings per share for the current year.

Wall Street Analysts Forecast Growth

DYN has been the subject of several research reports. Raymond James Financial restated a "strong-buy" rating and issued a $37.00 price objective on shares of Dyne Therapeutics in a report on Tuesday. Wall Street Zen lowered Dyne Therapeutics from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 1st. Cantor Fitzgerald assumed coverage on Dyne Therapeutics in a report on Thursday, July 23rd. They issued an "overweight" rating for the company. HC Wainwright reissued a "buy" rating and set a $50.00 price objective on shares of Dyne Therapeutics in a research note on Monday, August 17th. Finally, Morgan Stanley decreased their target price on shares of Dyne Therapeutics from $47.00 to $45.00 and set an "overweight" rating for the company in a research note on Friday, July 31st. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $34.17.

Institutional Investors Weigh In On Dyne Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. T. Rowe Price Investment Management Inc. raised its holdings in Dyne Therapeutics by 523.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company's stock worth $343,085,000 after acquiring an additional 14,727,667 shares during the last quarter. BlackRock Inc. purchased a new stake in Dyne Therapeutics in the second quarter worth about $275,500,000. Jupiter Topco LLC purchased a new position in shares of Dyne Therapeutics during the 2nd quarter valued at $266,634,000. State Street Corp raised its position in shares of Dyne Therapeutics by 27.0% during the fourth quarter. State Street Corp now owns 6,692,745 shares of the company's stock valued at $130,910,000 after buying an additional 1,423,828 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. increased its stake in Dyne Therapeutics by 45.5% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 5,172,000 shares of the company's stock worth $101,164,000 after acquiring an additional 1,618,000 shares during the last quarter. Institutional investors own 96.68% of the company's stock.

Key Headlines Impacting Dyne Therapeutics

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: Dyne will present six- and 12-month ACHIEVE data at the World Muscle Society and AANEM meetings on September 30. The presentations will compare a pooled treated group with a matched natural-history cohort and include updated safety information. Topline data from the fully enrolled registrational expansion cohort remain targeted for Q1 2027. Dyne ACHIEVE data announcement
• Positive Sentiment: Z-basivarsen has received FDA Breakthrough Therapy, Orphan Drug and Fast Track designations, while Dyne is advancing the program into the Phase 3 HARMONIA trial. These regulatory designations and upcoming data could provide future catalysts if clinical benefit is confirmed.
• Neutral Sentiment: Options activity was unusually high, with traders purchasing approximately 20,532 call contracts—more than 40 times the average daily call volume. This may reflect speculative positioning ahead of clinical presentations, but it does not establish a fundamental change in the company’s outlook.
• Neutral Sentiment: Several insiders, including CEO John Cox, Chief Medical Officer Douglas Kerr and Chief Commercial Officer Johanna Friedl-Naderer, reported small stock sales. The filings state that the transactions were made to cover tax withholding obligations from vested equity awards, reducing their negative significance.
• Negative Sentiment: Investor sentiment was pressured after a competing DM1 drug reportedly failed in a Phase 3 trial. The result may have increased concern about the difficulty of demonstrating meaningful clinical benefit in DM1 and raised the risk profile ahead of Dyne’s own data release. DM1 rival trial news
• Negative Sentiment: No company-specific negative clinical result was confirmed in the reports. However, the absence of new efficacy data today, combined with uncertainty surrounding the upcoming one-year results and the delay until Q1 2027 for registrational-cohort topline data, left DYN vulnerable to profit-taking and risk reduction. Dyne share decline report

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company's proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne's lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.